Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807598 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
A Phase 2 study of Systemic Mastocytosis and Aggressive Systemic Mastocytosis, sponsored by Jason Robert Gotlib.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT01807598 is a Phase 2 study of Systemic Mastocytosis and Aggressive Systemic Mastocytosis that has completed, run by Jason Robert Gotlib. The registered enrollment target is 10 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01807598, a Phase 2 study of Systemic Mastocytosis and Aggressive Systemic Mastocytosis, has completed, sponsored by Jason Robert Gotlib.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
Conditions Studied
Interventions
- DRUG Brentuximab vedotin
Study Locations (2)
California
- Stanford University, School of Medicine - Stanford
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807598
The ClinicalTrials.gov registry entry for NCT01807598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Robert Gotlib, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Systemic Mastocytosis appearing as the primary indexed condition, and to 1 intervention - of which Brentuximab vedotin is the first listed.
NCT01807598 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT01807598 about?
NCT01807598 is a clinical study titled "Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia". This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find ...
What is the current status of trial NCT01807598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-09. Estimated completion is 2017-09.
What conditions does trial NCT01807598 study?
This clinical trial studies the following conditions: Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Mast Cell Leukemia.
What interventions are being tested in trial NCT01807598?
The interventions under investigation include: Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT01807598?
This trial is sponsored by Jason Robert Gotlib, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01807598 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Mastocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.